A meta-analysis of four retrospective cohorts of patients with type 2 diabetes mellitus (T2DM) found that DPP4 inhibitor users had a 28% lower risk of incident RA compared with those who did not receive DPP4 inhibitors [10]. Here, DPP4 is linked to type 2 diabetes mellitus.